GlaxoSmithKline Pakistan Limited

KASE:GLAXO Stock Report

Market Cap: PK₨128.3b

GlaxoSmithKline Pakistan Past Earnings Performance

Past criteria checks 4/6

GlaxoSmithKline Pakistan's earnings have been declining at an average annual rate of -11.2%, while the Pharmaceuticals industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 10.4% per year. GlaxoSmithKline Pakistan's return on equity is 17.8%, and it has net margins of 8%.

Key information

-11.2%

Earnings growth rate

-11.2%

EPS growth rate

Pharmaceuticals Industry Growth20.2%
Revenue growth rate10.4%
Return on equity17.8%
Net Margin8.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How GlaxoSmithKline Pakistan makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KASE:GLAXO Revenue, expenses and earnings (PKR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2456,2334,5076,2250
30 Jun 2455,2732,5106,5000
31 Mar 2453,8786696,6720
31 Dec 2349,6615346,5280
30 Sep 2348,7771,2916,2740
30 Jun 2346,9331,5106,0620
31 Mar 2344,6151,9685,5510
31 Dec 2241,8422,4635,1390
30 Sep 2240,1783,2334,4820
30 Jun 2238,0784,2804,0140
31 Mar 2237,5935,5543,8750
31 Dec 2136,6615,3543,8570
30 Sep 2135,0823,9074,0630
30 Jun 2136,0693,8383,9500
31 Mar 2134,7503,6753,8180
31 Dec 2035,0903,3754,0640
30 Sep 2037,3423,6124,2190
30 Jun 2034,7013,4104,2550
31 Mar 2036,2482,9344,1920
31 Dec 1936,5823,0414,3080
30 Sep 1934,5583,1854,3510
30 Jun 1934,4362,8024,4520
31 Mar 1933,2522,8504,7560
31 Dec 1834,0073,2324,4590
30 Sep 1834,1652,6214,5380
30 Jun 1833,7902,8684,4010
31 Mar 1833,5073,1144,2800
31 Dec 1732,7743,0274,1300
30 Sep 1731,5973,2653,8360
30 Jun 1730,8553,1743,7560
31 Mar 1729,8402,9003,7210
31 Dec 1627,5642,6453,6410
30 Sep 1626,1712,1733,3430
30 Jun 1625,0622,7163,3490
31 Mar 1624,2012,6083,5730
31 Dec 1523,8222,5113,4780
30 Sep 1523,3222,4213,7080
30 Jun 1523,2381,5343,7560
31 Mar 1522,5801,5653,3620
31 Dec 1422,8431,5353,4580
30 Sep 1423,6511,2913,6970
30 Jun 1423,9441,0793,8030
31 Mar 1424,8751,1034,3010
31 Dec 1325,2311,0624,4770

Quality Earnings: GLAXO has high quality earnings.

Growing Profit Margin: GLAXO's current net profit margins (8%) are higher than last year (2.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: GLAXO's earnings have declined by 11.2% per year over the past 5 years.

Accelerating Growth: GLAXO's earnings growth over the past year (249%) exceeds its 5-year average (-11.2% per year).

Earnings vs Industry: GLAXO earnings growth over the past year (249%) exceeded the Pharmaceuticals industry 56%.

Return on Equity

High ROE: GLAXO's Return on Equity (17.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 08:21
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GlaxoSmithKline Pakistan Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution